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at today's Family Medicine CME conference.  I 
do not own any equity positions in the any of the 
pharmaceutical companies that manufacture the 
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• A 54 year-old male with type 2 diabetes and early CKD stage 3 
felt to be secondary to diabetic nephropathy comes to your office 
for follow up.  BP's at home on losartan 50 mg/day and 
chlorthalidone 12.5 mg/day are 150/95 mm Hg.  BP is 154/94 mm 
Hg and there is no edema.  Creatinine is 1.5 mg/dL, e GFR is 52 
ml/min, and urine P/C ratio is 0.8.  
Clinical Case # 1
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Which of the following is the most appropriate next step to treat his 
hypertension and proteinuria in diabetic nephropathy?
• Double losartan to 100 mg/day 
• Double chlorthalidone to 25 mg/day
• Add lisinopril 10 mg/day
• Add amlodipine 5 mg/day
• Add carvedilol 12.5 mg bid
Clinical Case # 1:
Question
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• Purpose of the paper
• Designed to test the safety and efficacy of 
combination therapy ACE inhibitor and an 
ARB as compared with ARB mono therapy
• 1448 VA patients with type 2 DM and DN 
were randomized to losartan plus lisinopril vs 
losartan mono therapy for 48 months  
Combined Angiotensin Inhibition for 
the Treatment of Diabetic 
Nephropathy
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• Primary end points
• Decline in e GFR
• ESRD
• Death
Combined Angiotensin Inhibition for 
the Treatment of Diabetic 
Nephropathy
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• Secondary end points
• First occurrence of a decline in eGFR
• Tertiary end points
• Cardiovascular events
• Change the slope of the e GFR
• Change in albuminuria in one year
Combined Angiotensin Inhibition for the 
Treatment of Diabetic Nephropathy
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• Adverse events and safety
• All cause mortality
• AKI
• Hyperkalemia
• [K+] > 6.0 meq/L
Combined Angiotensin Inhibition for 
the Treatment of Diabetic 
Nephropathy
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• Study terminated early in October of 
2012
• Safety concerns over the following 
adverse events
• AKI
• Hyperkalemia
Combined Angiotensin Inhibition for 
the Treatment of Diabetic 
Nephropathy
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• Recommendation:  Avoid combination therapy with ACE 
inhibitors and ARB's in patients with diabetic nephropathy
• No benefit in outcomes in any parameters measured
• Higher incidence of complications
• Unanswered questions: 
• Do these findings apply to other renal diseases and other 
populations other than patients with diabetic nephropathy?
• Do these findings apply to combining ACE inhibitors or ARB's 
with aldosterone receptor antagonists such as 
spironolactone? 
Combined Angiotensin Inhibition for the 
Treatment of Diabetic Nephropathy: 
Take home points
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• A 51 year old Caucasian female with type 2 diabetes for 7 years 
and stage 3 CKD comes to your office for follow up.  She is taking 
glyburide 5 mg/day, lisinopril 20 mg/day and chlorthalidone 12.5 
mg every other day.  Her BMI is 34, BP is 130/85 mm Hg, and 
there is no edema.  Creatinine is 1.3 mg/dL with an e GFR of 46 
ml/min.  Hgb A1C is 8.1%.  
Clinical Case # 2
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• Which of the following would you do to treat her diabetes and lower 
her Hgb A1C?
• Double glyburide to 10 mg/day
• Discontinue glyburide and start glipizide at 20 mg/day
• Begin insulin therapy
• Begin metformin at 500 mg/day and increase to 2000 mg/day to 
achieve target A1C
Clinical Case # 2:
Question
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• Purpose of the Paper
• To review whether or not there is truly an 
increased incidence of metformin associated 
lactic acidosis (MALA) in patients with 
impaired kidney function
Metformin in Patients with 
Type 2 Diabetes and Kidney 
Disease:  A Systematic 
Review
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• 65 papers selected between 1950-2014 that 
were of the following categories:
• Pharmacokinetic/metabolic investigations: 
10
• Case series:  20
• Cross-sectional, observational, and 
pharmacosurveillance:  31
• Meta analyses:  3
• Clinical trial: 1
Metformin in Patients with 
Type 2 Diabetes and Kidney 
Disease:  A Systematic 
Review
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• Current labeling guidelines from the FDA
Metformin in Patients with 
Type 2 Diabetes and Kidney 
Disease:  A Systematic 
Review
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• Although metformin clearance is decreased 
in CKD, drug levels remain within the 
therapeutic range when the e GFR is > 30 
ml/min
• No consistent link between metformin and 
lactic acidosis has been found
• Incidence of lactic acidosis is rare 
• Frequency of lactic acidosis in patients 
taking metformin is very low
Metformin in Patients with 
Type 2 Diabetes and Kidney 
Disease:  A Systematic 
Review
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• Conclusion from the data reviewed:
• As long as kidney function is stable and the 
patient is observed closely, metformin is 
unlikely to measurably increase the risk of 
lactic acidosis in those with mild to moderate 
CKD 
• e GFR:  30-60 ml/min
Metformin in Patients with 
Type 2 Diabetes and Kidney 
Disease:  A Systematic 
Review
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• Drug levels and lactate levels in patients with stage 3 CKD 
generally remain within the therapeutic and normal range, 
respectively
• The overall incidence of lactic acidosis in metformin users is 
indistinguishable for the background rate in the overall 
population with diabetes
• Observational studies suggest a potential benefit from 
metformin on micro-vascular outcomes in patients with CKD
• Caution:  No benefit in macro-vascular complications when 
A1C is “Optimal” at 7.0%
• Expansion of metformin use in patients with Stage 3 CKD 
seems appropriate given the potential benefit and over the 
implied risk
Expanded use of metformin 
in patients with CKD: 
Take home points
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• A 45 year old male with CKD stage 3 is seen in your office for a 
routine appointment.  He is feeling well and has no complaints. 
Current medications include lisinopril, insulin, amlodipine, and 
spironolactone.  PE reveals a BP of 131/80 mm Hg.  There are no 
crackles and there is no edema. Labs reveal  [K+] of 5.9 meq/L.  
Urine protein/creatinine ratio is 0.4   Creatinine is stable at 1.7 
mg/dL. 
• You counsel him on dietary K+ intake and prescribe chlorthalidone, 
12.5 mg/day
• He returns 4 weeks later without any complaints and he states he 
has implemented the dietary and medication change(s) from the last 
visit
• [K+] in 5.6 meq/L
Clinical Case # 3
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• Which of the following would you recommend next to treat his 
hyperkalemia?
• Stop the lisinopril
• Stop the spironolactone
• Prescribe Sodium polystyrene sulfonate (Kayexalate) 
• Prescribe Patiromer 8.4 grams bid
• Double the chlorthalidone to 25 mg/day
Clinical Case # 3:
Question
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• Purpose of the paper
• To evaluate the safety and efficacy of 
patiromer in patients with chronic kidney 
disease who were receiving at least one RAAS 
inhibitor and who had hyperkalemia. 
Patiromer in Patients with Kidney Disease and 
Hyperkalemia Receiving RAAS Inhibitors 
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What is Patiromer?
• Patiromer
• Non absorbed spherical bead that binds 
potassium in exchange for calcium
• Works predominantly in the distal colon
• FDA approved for the treatment of 
hyperkalemia in 2015
• Very little of the drug is absorbed so little 
calcium is absorbed
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Patiromer in Patients with Kidney Disease 
and 
Hyperkalemia Receiving RAAS Inhibitors 
• Study design
• Single blind treatment phase for 4 weeks
• 4.2 or 8.4 grams of Patiromer initially
• Up to 21.4 grams needed to achieve goal 
[K+]
• Placebo controlled randomized withdrawal 
phase for 8 weeks
• Patiromer or placebo 
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Patiromer in Patients with Kidney Disease 
and Hyperkalemia Receiving RAAS 
Inhibitors 
• Safety and tolerability
• Monitoring of adverse events
• Hypokalemia:  3.0%
• GI side effects: Most common
• Constipation: 11%
• Diarrhea:  3%
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• New agent FDA approved in 2015:  Patiromer
• Allow patients to safely continue RAAS inhibitors that 
seem to benefit them the most
• Poised to replace resin therapy as a safe long-term 
oral therapy for hyperkalemia
• Unanswered questions
• Will this agent be useful in treating acute 
hyperkalemia?
• Will the potassium lowering effect be maintained 
for greater than 28 days?
• Long Term Safety profile:  Unknown
New therapies for the treatment of 
hyperkalemia:  Take home points
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• At the conclusion of this activity, members of the 
audience will be able to
• Apply the principles of EBM to make decisions 
about the dual blockade of the RAAS in treating 
patients with hypertension or CKD with 
proteinuria
• Determine which patients with type 2 DM and 
CKD would benefit from the use of metformin 
without the risk of lactic acidosis
• Evaluate the safety and efficacy of a new oral 
medication approved for the treatment of 
hyperkalemia
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• Combination angiotensin inhibition for the treatment 
of diabetic nephropathy has no proven benefit and 
increases the risk for AKI and hyperkalemia
• Expanded use of metformin in CKD stage 3 
appears safe and awaiting FDA approval for 
expanded use in this patient population 
• Newer therapies for long term treatment of 
hyperkalemia may allow for ongoing use of agents 
that block the RAAS that are often prescribed in 
CKD
Conclusion
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